Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Expected to Reach $3,528.8 Million, by 2026

By -
Acute lymphocytic/lymphoblastic leukemia therapeutics market size was valued at $2,334.5 million in 2018, and is projected to reach $3,528.8 million by 2026, growing at a CAGR of 5.3% from 2019 to 2026.
Acute lymphocytic/lymphoblastic leukemia (ALL) is one of the types of leukemia, which is highly prevalent in pediatrics and also observed in adults. There are various therapy options for ALL treatment including chemotherapy, targeted therapy, and immunotherapy. ALL treatments witness high success rates in pediatric population, however, in adult population have low success rates. Chemotherapy is a first line treatment option in majority of ALL cases.
Rise in incidences of acute lymphoblastic leukemia and the number of bone marrow biopsies across the world are the major factors that boost the growth of the acute lymphocytic/lymphoblastic leukemia therapeutics market. However, the stringent regulatory approvals for the therapeutics and the adverse side effect of the drugs used in the therapy impede the acute lymphocytic/lymphoblastic leukemia therapeutics market growth. The increase in investment in the R&D of different leukemia and rise in awareness of targeted therapies amongst the population are also anticipated to provide lucrative opportunities for the market during the forecast period.
On the basis of drug, the Hyper-CVAD Regimen acquired the largest acute lymphocytic/lymphoblastic leukemia therapeutics market share in 2018 owing to their wide usage in ALL treatment. Hyper-CVAD Regimen is considered as one of the most commonly used therapy options for acute lymphocytic/lymphoblastic leukemia. Furthermore, targeted drugs & immunotherapy are projected to grow at the fastest rate during the forecast period as these drugs have shown potential in treatment of relapsed acute lymphocytic leukemia and is widely used in patients who do not respond to chemotherapy. Therefore, these factors contribute toward the growth of the acute lymphocytic/lymphoblastic leukemia therapeutics market.
According to type, the pediatrics segment generated the highest revenue in 2018 and is expected to maintain its dominance throughout the forecast period. This is attributed to the high incidences of acute lymphocytic/lymphoblastic leukemia among pediatric population. Acute lymphocytic/lymphoblastic leukemia is considered as one of the most common cancer types in pediatric population. Moreover, pediatric population has higher success rate for acute lymphocytic/lymphoblastic leukemia treatments.
In 2018, North America occupied the largest share of the market and is expected to maintain its dominance during the forecast period owing to easy availability of treatments, high cost of treatments, and presence of majority of key players. On the other side, Asia-Pacific is estimated to register the fastest growth during the forecast period

Key Findings of the Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market:

  • The pediatrics segment accounted for more than half of the market share in 2018.
  • North America accounted for more than one-third market share in 2018 and is expected to maintain this trend throughout the forecast period.
  • The targeted drugs & immunotherapy in the end user segment is anticipated to grow at a CAGR of 6.7% from 2018 to 2026.
  • The adults segment accounted for 44% share of the market in 2018.

Comments

Post a Comment

Popular posts from this blog

Global Cancer pain market is segmented based on drug type, disease indication, and region.

By -
According to a new report published by Allied Market Research, titled, "Cancer Pain Market by Type and Application: Global Opportunity Analysis and Industry Forecast, 2018 - 2025,"  the global cancer pain market was valued at $5,285 million in 2017, and is expected to reach $7,545 million by 2025, growing at a CAGR of 4.5% from 2018 to 2025. Download the Sample Report @  https://www.alliedmarketresearch.com/request-sample/5123?utm_source=Blogger&utm_medium=Niranjan Cancer pain is chronic in nature and is commonly associated with cancer. It results from tissue damage, either due to the disease itself or due to different treatments such as chemotherapy, radiotherapy, or surgery. Cancer pain drugs are expected to exhibit significant market growth during the forecast period due to growth in demand for the drugs, surge in prevalence of cancer across the globe, increase in number of R&D activities to develop ideal cancer pain medications, and rise in the unmet nee...
Read more

U.S. was the largest country market in 2015, and is projected to maintain its lead until 2022.

By -
Image
  Surge in usage of wireless monitoring devices and increase in population of aging people across the globe drive the growth of the global patient monitoring devices market. However, high cost associated with patient monitoring devices is anticipated to restrain the market growth. Furthermore, increasing technological advancements are expected to provide new opportunities during the forecast period. The  Patient Monitoring Devices Market  generated $25.76 billion in 2019, and is estimated to reach $44.86 billion by 2027, registering a CAGR of 4.4% from 2020 to 2027. Based on product type, the cardiac monitoring devices segment contributed to the largest share in 2019, accounting for more than one-fourth of the total share, and is estimated to maintain its dominant position during the forecast period. However, the remote patient monitoring devices segment is estimated to portray the highest CAGR of 6.3% during the forecast period. Based on end-user, the hospitals segment a...
Read more